These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 3487691)
21. Relative sparing of the dopaminergic innervation of the globus pallidus in monkeys made hemi-parkinsonian by intracarotid MPTP infusion. Schneider JS; Dacko S Brain Res; 1991 Aug; 556(2):292-6. PubMed ID: 1682010 [TBL] [Abstract][Full Text] [Related]
22. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? German DC; Dubach M; Askari S; Speciale SG; Bowden DM Neuroscience; 1988 Jan; 24(1):161-74. PubMed ID: 3259295 [TBL] [Abstract][Full Text] [Related]
23. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment. Alexander GM; Schwartzman RJ; Grothusen JR; Brainard L; Gordon SW Brain Res; 1993 Oct; 625(2):276-82. PubMed ID: 8275309 [TBL] [Abstract][Full Text] [Related]
24. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758 [TBL] [Abstract][Full Text] [Related]
26. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115 [TBL] [Abstract][Full Text] [Related]
27. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Jenner P; Marsden CD J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760 [TBL] [Abstract][Full Text] [Related]
28. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. Palombo E; Porrino LJ; Bankiewicz KS; Crane AM; Sokoloff L; Kopin IJ J Neurosci; 1990 Mar; 10(3):860-9. PubMed ID: 2319306 [TBL] [Abstract][Full Text] [Related]
29. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Mochizuki H; Imai H; Endo K; Yokomizo K; Murata Y; Hattori N; Mizuno Y Neurosci Lett; 1994 Feb; 168(1-2):251-3. PubMed ID: 8028787 [TBL] [Abstract][Full Text] [Related]
30. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. Schultz W; Studer A; Jonsson G; Sundström E; Mefford I Neurosci Lett; 1985 Aug; 59(2):225-32. PubMed ID: 3877257 [TBL] [Abstract][Full Text] [Related]
31. Behavioral evaluation of hemiparkinsonian MPTP monkeys following dopamine pharmacological manipulation and adrenal co-graft transplantation. Howel LL; Byrd LD; McDonough AM; Iuvone PM; Bakay RA Cell Transplant; 2000; 9(5):609-22. PubMed ID: 11144958 [TBL] [Abstract][Full Text] [Related]
32. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography. Robertson RG; Clarke CA; Boyce S; Sambrook MA; Crossman AR Brain Res; 1990 Oct; 531(1-2):95-104. PubMed ID: 2289139 [TBL] [Abstract][Full Text] [Related]
33. Estradiol and dehydroepiandrosterone potentiate levodopa-induced locomotor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Bélanger N; Grégoire L; Bédard P; Di Paolo T Endocrine; 2003 Jun; 21(1):97-101. PubMed ID: 12777709 [TBL] [Abstract][Full Text] [Related]
34. Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment. Benazzouz A; Boraud T; Féger J; Burbaud P; Bioulac B; Gross C Mov Disord; 1996 Nov; 11(6):627-32. PubMed ID: 8914087 [TBL] [Abstract][Full Text] [Related]
35. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Cohen G; Pasik P; Cohen B; Leist A; Mytilineou C; Yahr MD Eur J Pharmacol; 1984 Oct; 106(1):209-10. PubMed ID: 6442232 [No Abstract] [Full Text] [Related]
36. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. Burns RS; Markey SP; Phillips JM; Chiueh CC Can J Neurol Sci; 1984 Feb; 11(1 Suppl):166-8. PubMed ID: 6608980 [TBL] [Abstract][Full Text] [Related]
37. In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. Skirboll S; Wang J; Mefford I; Hsiao J; Bankiewicz KS Exp Neurol; 1990 Nov; 110(2):187-93. PubMed ID: 1699780 [TBL] [Abstract][Full Text] [Related]
38. Motor and nonmotor behavioral deficits in monkeys made hemiparkinsonian by intracarotid MPTP infusion. Schneider JS; McLaughlin WW; Roeltgen DP Neurology; 1992 Aug; 42(8):1565-72. PubMed ID: 1641154 [TBL] [Abstract][Full Text] [Related]
39. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease? Allen JM; Cross AJ; Yeats JC; Ghatei MA; McGregor GP; Close SP; Pay S; Marriott AS; Tyers MB; Crow TJ Brain; 1986 Feb; 109 ( Pt 1)():143-57. PubMed ID: 2417654 [TBL] [Abstract][Full Text] [Related]
40. Development of a model for Parkinson's disease in sheep using unilateral intracarotid injection of MPTP via slow continuous infusion. Baskin DS; Browning JL; Widmayer MA; Zhu ZQ; Grossman RG Life Sci; 1994; 54(7):471-9. PubMed ID: 8309350 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]